

Supplementary Table S1: Patient characteristics by center.

	All Patients N = 154	Center 1 N = 49	Center 2 N = 28	Center 3 N = 77	P value
Age - Median (Range)	62 (37, 83)	60 (39, 81)	63 (39, 79)	62 (37, 83)	0.245
Gender - No. (%)					
Male	86 (56)	30 (61)	10 (36)	46 (60)	0.06
Female	68 (44)	19 (39)	18 (64)	31 (40)	
Race - No. (%)					
African American	12 (9)	8 (16)	1 (7)	3 (4)	0.047
Caucasian	120 (86)	38 (78)	13 (87)	69 (91)	
Hispanic	3 (2)	2 (4)	1 (7)	0 (0)	
Asian	5 (4)	1 (2)	0 (0)	4 (5)	
Missing	14	0	13	1	
Stage - No. (%)					
Locally Advanced	37 (24)	18 (37)	10 (36)	9 (12)	0.001
Metastatic	117 (76)	31 (63)	18 (64)	68 (88)	
Grade - No. (%)					
Well- differentiated	3 (2)	3 (6)	0 (0)	0 (0)	0.366
Moderately- differentiated	31 (20)	11 (22)	5 (18)	15 (19)	
Poorly- differentiated	15 (10)	6 (12)	2 (7)	7 (9)	
Unknown	105 (68)	29 (59)	21 (75)	55 (71)	
ECOG - No. (%)					
0	44 (29)	20 (41)	6 (23)	18 (24)	0.084
1	100 (66)	29 (59)	19 (73)	52 (68)	
2	7 (5)	0 (0)	1 (4)	6 (8)	
Missing	3	0	2	1	
Number of Comorbidities - Median (Range)	2 (0, 8)	2 (0, 8)	2 (0, 5)		
Family History of Cancer - No. (%)					
Yes	115 (77)	35 (73)	13 (52)	67 (87)	0.001
No	35 (23)	13 (27)	12 (48)	10 (13)	
Missing	4	1	3	0	
Family History of Pancreas Cancer - No. (%)					
Yes	7 (10)	6 (12)	1 (4)	0 (NaN)	0.412
No	65 (90)	42 (88)	23 (96)	0 (NaN)	
Missing	82	1	4	77	
Number of Cycles - Median (Range)	4 (1, 40)	4 (1, 27)	4 (1, 20)	4 (1, 40)	0.856
Number of Metastatic Sites - No. (%)					
0	22 (29)	17 (35)	5 (19)	0 (NaN)	0.292
1	33 (43)	19 (39)	14 (52)	0 (NaN)	
2	16 (21)	11 (22)	5 (19)	0 (NaN)	
3	5 (7)	2 (4)	3 (11)	0 (NaN)	
Missing	78	0	1	77	
Prior Chemotherapy - No. (%)					
No	79 (51)	34 (69)	14 (50)	31 (40)	0.006
Yes	75 (49)	15 (31)	14 (50)	46 (60)	
Previous Surgery - No. (%)					
Yes	16 (21)	8 (16)	8 (29)	0 (NaN)	0.248
No	61 (79)	41 (84)	20 (71)	0 (NaN)	
Missing	77	0	0	77	
Line of GTX Therapy - No. (%)					
1st	79 (51)	34 (69)	14 (50)	31 (40)	0.037
2 nd or greater	75 (49)	15 (31)	14 (50)	46 (60)	
Ascites - No. (%)					
Yes	25 (16)	14 (29)	7 (25)	4 (5)	< 0.001
No	129 (84)	35 (71)	21 (75)	73 (95)	

Supplementary Table S2: Frequency of toxicities, overall and by center.

	All Patients N = 154	Center 1 N = 49	Center 2 N = 28	Center 3 N = 77	P value
Any Grade 3/4 Hematological Toxicity - No. (%)					
No	90 (59)	25 (52)	16 (59)	49 (64)	0.468
Yes	62 (41)	23 (48)	11 (41)	28 (36)	
Missing	2	1	1	0	
Thrombocytopenia- No. (%)					
Grade 1/2	80 (68)	28 (58)	18 (67)	34 (79)	< 0.001
Grade 3/4	15 (13)	5 (10)	1 (4)	9 (21)	
None	23 (19)	15 (31)	8 (30)	0 (0)	
Missing	36	1	1	34	
Neutropenia - No. (%)					
Grade 1/2	41 (36)	10 (21)	8 (30)	23 (59)	< 0.001
Grade 3/4	39 (34)	17 (35)	9 (33)	13 (33)	
None	34 (30)	21 (44)	10 (37)	3 (8)	
Missing	40	1	1	38	
Leucopenia - No. (%)					
Grade 1/2	69 (57)	24 (50)	19 (70)	26 (58)	0.124
Grade 3/4	35 (29)	13 (27)	6 (22)	16 (36)	
None	16 (13)	11 (23)	2 (7)	3 (7)	
Missing	34	1	1	32	
Anemia - No. (%)					
Grade 1/2	129 (85)	41 (85)	24 (89)	64 (83)	0.99
Grade 3/4	19 (12)	6 (12)	3 (11)	10 (13)	
None	4 (3)	1 (2)	0 (0)	3 (4)	
Missing	2	1	1	0	
Any Grade 3/4 Non-Hematological Toxicity - No. (%)					
No	138 (91)	44 (92)	25 (96)	69 (90)	0.632
Yes	13 (9)	4 (8)	1 (4)	8 (10)	
Missing	3	1	2	0	
Elevated ALT - No. (%)					
Grade 1/2	75 (50)	24 (50)	10 (38)	41 (53)	0.316
Grade 3/4	9 (6)	4 (8)	0 (0)	5 (6)	
None	67 (44)	20 (42)	16 (62)	31 (40)	
Missing	3	1	2	0	
Bilirubin - No. (%)					
Grade 1/2	35 (35)	9 (19)	8 (31)	18 (72)	< 0.001
Grade 3/4	5 (5)	0 (0)	1 (4)	4 (16)	
None	59 (60)	39 (81)	17 (65)	3 (12)	
Missing	55	1	2	52	
Hospitalizations - No. (%)					
None	51 (67)	33 (69)	18 (64)	0 (NaN)	0.801
1 or more	25 (33)	15 (31)	10 (36)	0 (NaN)	
Missing	78	1	0	77	

Supplementary Table S3: Adjusted odds ratios for the risk of grade 3/4 toxicity.

	No Grade 3/4 Toxicities N = 83	Grade 3/4 Toxicities N = 69	Adjusted OR	95% CI	P
Stage - No. (%)					
Locally Advanced	15 (18)	21 (30)	1.00	-	
Metastatic	68 (82)	48 (70)	0.57	(0.24,1.33)	0.192
Stage/GTX - No. (%)					
Locally Advanced	15 (18)	21 (30)	1.00	-	
Mets, 1st Line	33 (40)	17 (25)	0.43	(0.17,1.09)	0.143
Mets, 2nd, Line	35 (42)	31 (45)	0.81	(0.3,2.13)	
Grade - No. (%)					
Well or moderately differentiated	18 (22)	16 (23)	1.00	-	
Poorly- differentiated or Unknown	65 (78)	53 (77)	1.11	(0.48,2.54)	0.807
ECOG - No. (%)					
0	24 (29)	19 (28)	1.00	-	
1+	58 (71)	48 (72)	1.16	(0.53,2.54)	0.709
Prior Chemotherapy - No. (%)					
No	47 (57)	31 (45)	1.00	-	
Yes	36 (43)	38 (55)	2.01	(0.97,4.16)	0.057
Previous Surgery - No. (%)					
Yes	8 (21)	7 (19)	1.00	-	
No	31 (79)	29 (81)	1.37	(0.33,5.58)	0.663
Ascites - No. (%)					
Yes	15 (18)	10 (14)	1.00	-	
No	68 (82)	59 (86)	1.32	(0.49,3.56)	0.579
Hospitalizations - No. (%)					
None	28 (72)	23 (64)	1.00	-	
1 or more	11 (28)	13 (36)	1.36	(0.45,4.1)	0.587

Supplementary Table S4: Estimates of OS (time from start of GTX therapy to death) for patients who received their 2nd+ line of GTX. Values are OS [95% CI].

	N	Median OS (months)	1y OS	HR	95% CI	P
All Patients	75	5.7	32 [22, 46]			
All Patients, by Staging						
LAPC	8	16.17	64 [34, 100]	1.00	-	
Mets	67	5.67	29 [19, 44]	0.91	(0.18,4.51)	0.905
Grade						
Well or moderately differentiated	19	15.97	57 [37, 88]	1.00	-	
Poorly- differentiated or Unknown	56	5.67	24 [14, 40]	1.28	(0.61,2.68)	0.518
ECOG						
0	16	12.4	57 [36, 91]	1.00	-	
1+	57	5.67	25 [15, 42]	1.69	(0.8,3.54)	0.167
Previous Surgery						
No	17	9.13	30 [12, 75]	0.96	-	
Yes	12	17.23	63 [21, 100]	0.25	(0.06,0.96)	0.044
Hospitalizations						
None	19	10.47	45 [25, 82]	1.00	-	
1 or more	10	11.93	47 [21, 100]	1.06	(0.23,4.96)	0.941
Any Grade 3/4 Toxicity						
No	36	5.4	20 [10, 41]	1.00	-	
Yes	38	7.47	44 [29, 67]	0.47	(0.25,0.9)	0.022
Family history of cancer						
No	16	7.47	34 [16, 73]	1.00	-	
Yes	58	5.7	32 [21, 49]	0.50	(0.21,1.17)	0.109
Comorbidities						
None	5	10.53	25 [5, 100]	1.00	-	
1 or more	24	12.4	52 [33, 82]	0.24	(0.01,6.74)	0.404
Neutropenia						
No	12	8.93	17 [3, 81]	1.00	-	
Yes	38	13.23	53 [37, 75]	0.37	(0.14,1)	0.051
Elevated ALT						
No	43	5.4	28 [16, 49]	1.00	-	
Yes	31	7.73	39 [24, 62]	0.77	(0.41,1.45)	0.42
Change in CA19 from baseline						
<25%	20	4.87	37 [19, 74]	1.00	-	
25-50%	7	8.9	50 [22, 100]	0.85	(0.22,3.36)	0.709
50-75%	6	7.73	20 [3, 100]	1.29	(0.36,4.57)	
>75%	16	8.5	49 [29, 81]	0.64	(0.24,1.73)	
RECIST based response						
Partial Response	2	25.65	100 [100, 100]	1.00	-	
Stable Disease	41	9.47	44 [29, 66]	2.06	[0.43, 9.75]	
Progressive Disease	27	3.93	13 [5, 38]	5.03	[1.00, 25.3]	0.021
Missing	5	1.83	0 -			

LAPC – Locally-advanced pancreatic cancer